Ann Mullally: Expect to See Lots More Gene Therapy in Medicine in the Years Ahead
Ann Mullally, Professor at Stanford University School of Medicine, Division Chief of Hematology at Stanford Department of Medicine, Principal Investigator at Mullally Lab, shared Stanford Department of Medicine‘s post on LinkedIn:
“Expect to see lots more gene therapy in medicine in the years ahead!
One of many inspiring messages from Katherine High during her visit to Stanford Division of Hematology this week – a trailblazer in treating hemophilia with gene therapy, it was an honor to host Dr. High with Stanford Department of Medicine and to learn more about her pioneering work and exciting career!”
Stanford Department of Medicine shared a post on LinkedIn:
“Gene therapy pioneer Katherine High, delivered the Stanley Schrier Lecture at this week’s Medicine Grand Rounds.
High is the co-founder of Spark Therapeutics, Inc., winner of the 2026 Breakthrough Prize in Life Sciences and leader of the team that won FDA approval for Luxturna, the first gene therapy for an inherited disease.”
Stay updated with Hemostasis Today.
-
Sep 27, 2026, 15:49Rana Al-Hrout: Iron Deficency – Is Ferritin 15ng/mL or Less Still the Cutoff?
-
Sep 27, 2026, 15:49Ayushi Sharma: What I Thought Transfusion Medicine Would Be vs What It Actually Is
-
Sep 27, 2026, 15:48William Wallace: How Much Human Research Is Behind the Supplements We Take?
-
Sep 27, 2026, 15:46Franck Perraudin: Lp(a) Lowering Alone May Not Be Enough
-
Sep 27, 2026, 15:41Ahmed Hamandi: Sharing Real-World HSCT Experience at the Iraqi Society of Haematology Conference
-
Sep 27, 2026, 15:39Co-creating Digital Support With Young Stroke Survivors – European Stroke Organisation
-
Sep 27, 2026, 15:39Eleri Schiavone: Celebrating 80 Years of the Welsh Blood Service
-
Sep 27, 2026, 15:38Jessica Garcia: Standing Where VWD Was First Recognized 100 Years Later
-
Sep 27, 2026, 15:37Heghine Khachatryan: A Meaningful Step Forward for Inherited Blood Disorders in Africa